Lite Strategy, Inc. is a pharmaceutical company focused on developed and differentiated cancer therapies. The Company's drug candidate pipeline includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor, zandelisib, an oral, once-daily, selective PI3Kd inhibitor. CDK9 functions in cell cycle regulation, and its modulation in cancer and autoimmune diseases. It is a transcriptional regulator of the myeloid leukemia cell differentiation protein (Mcl-1). Zandelisib is an oral, once-daily, selective PI3Kd inhibitor that is developed for the treatment of indolent B-cell lymphomas. Its approach to pre-clinical drug development is to evaluate its drug candidates in combination with standard-of-care therapies to overcome known resistance mechanisms and address medical needs. It holds Litecoin (LTC) tokens as a primary asset as part of an institutional treasury. LTC is an open source, global payment network that is decentralized without any central authorities.
Back to dashboard
Company Information
About this company
Key people
Frederick W. Driscoll
Independent Chairman of the Board
Justin J. File
Chief Executive Officer, Chief Financial Officer, Company Secretary, Director
Charles B. Lee
Director
Joshua Riezman
Director
James Flynn
Independent Director
Nicholas R. Glover
Independent Director
Click to see more
Key facts
- Shares in issue34.79m
- EPICLITS
- ISINUS55279B3015
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap$42.57m
- Employees5
- ExchangeNASDAQ
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.